Biologically Active Small Molecules

A selective activator of PKM2 (AC₅₀ = 38 nM in vitro, EC₅₀ = 19.6 &microM in cells) converts PKM2 to a constitutively active enzyme state that is resistant to inhibition by tyrosine-phosphorylated proteins.

A selective activator of PKM2 (AC₅₀ = 38 nM in vitro, EC₅₀ = 19.6 &microM in cells) converts PKM2 to a constitutively active enzyme state that is resistant to inhibition by tyrosine-phosphorylated proteins.

A potent inhibitor of the non-receptor tyrosine kinases Abl and Src as well as other members of the Src family inhibits Abl, Src, and Lck with IC50 values of 0.05, 0.

A potent inhibitor of the non-receptor tyrosine kinases Abl and Src as well as other members of the Src family inhibits Abl, Src, and Lck with IC50 values of 0.05, 0.

A potent inhibitor of the non-receptor tyrosine kinases Abl and Src as well as other members of the Src family inhibits Abl, Src, and Lck with IC50 values of 0.05, 0.

A fluorescent fatty acid analog that alters its fluorescent emission spectra and intensity on entry into binding proteins.

A fluorescent fatty acid analog that alters its fluorescent emission spectra and intensity on entry into binding proteins.

A fluorescent fatty acid analog that alters its fluorescent emission spectra and intensity on entry into binding proteins.

An antitumor antibiotic that induces apoptosis in mature monocytic U937 and myelocytic HL-60 acute myeloid leukemia cells at 0.2-1 &muM triggers a ROS-dependent sphingomyelin-ceramide pathway that activates the MEKK1-SEK1-JNK.

An antitumor antibiotic that induces apoptosis in mature monocytic U937 and myelocytic HL-60 acute myeloid leukemia cells at 0.2-1 &muM triggers a ROS-dependent sphingomyelin-ceramide pathway that activates the MEKK1-SEK1-JNK.

An antitumor antibiotic that induces apoptosis in mature monocytic U937 and myelocytic HL-60 acute myeloid leukemia cells at 0.2-1 &muM triggers a ROS-dependent sphingomyelin-ceramide pathway that activates the MEKK1-SEK1-JNK.

An antitumor antibiotic that induces apoptosis in mature monocytic U937 and myelocytic HL-60 acute myeloid leukemia cells at 0.2-1 &muM triggers a ROS-dependent sphingomyelin-ceramide pathway that activates the MEKK1-SEK1-JNK.